Lobe Sciences Ltd. appointed Dr. David Kideckel, PhD, MBA, as Chief Financial Officer effective September 1, 2026.

Lobe Sciences Ltd. is a Canadian public biopharmaceutical company focused on advancing high-potential therapeutic assets through disciplined pharmaceutical development. The Company identifies, develops, and de-risks programs addressing unmet medical needs, then partners with established organizations for late-stage development and commercialization. Our shares trade on the Canadian Securities Exchange (CSE: LOBE), OTCQB (LOBEF), and Frankfurt Stock Exchange (FWB: LOBE). Through our majority-owned subsidiaries, Cynaptec Pharmaceuticals and Applied Lipid Technologies (ALT), we advance programs within focused entities designed to isolate risk, align capital, and progress assets independently through clinical development.

Founded 2018